TAK

TAK EBITDA Growth

8.31%TTM

Period ending:

TAK TTM EBITDA YoY %%
TAK TTM EBITDA YoY %1024.95%-247.79%
2010-06-302026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

TAK ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 65 observations from Jun 30, 2010 to Jun 30, 2026.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
8.3063%
17.5235%
4.997%
-18.8954%
5.3769%
2.919%
34.853%
27.4105%
-6.7907%
-8.8675%
-15.9211%
2.0105%
20.5258%
13.2268%
0.9468%
-8.951%
-8.476%
9.4167%
35.2265%
49.5373%
41.3414%
55.5945%
27.2007%
38.7396%
62.6455%
38.8633%
90.0326%
47.5847%
40.6688%
1.7001%
-24.4968%
-11.3359%
-19.0722%
23.0914%
18.1168%
7.3001%
-2.1563%
9.4995%
496.4487%
222.1999%
260.8689%
151.3223%
-85.8197%
-71.2971%
-73.1373%
-69.3804%
27.0504%
35.1734%
46.2559%
53.6111%
489.1234%
901.7838%
138.9486%
3.4437%
-124.6254%
-92.2911%
-72.6725%
-43.9204%
-19.6248%
-14.7193%
-6.4392%
-9.6935%
-12.5555%
-17.7439%
-12.3228%

Compare ebitda growth

All TAK financial metrics · TAK stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.